– COMPARISON OF CELLULAR RESPONSE OF TREATED MDA-MB231 BREAST CELLS REPOSITIONING EXISTING DRUGS AS NOVEL THERAPEUTICS FOR HIGH-RISK PAEDIATRIC LEUKAEMIA
A phenotypic was performed against HR leukaemia cell lines with a tailored compound library of 3707 approved drugs and pharmacologically active compounds. studies. OC potently induced autophagy in SK-BR-3 by upregulation of LCA/B, Atg-3, Atg-7, Atg-16L within 6 – 12 hour treatment. OC had no effect on the viability of the non-tumorigenic MCF-12A and RSC 96 cells. In vivo , 5 – 10 mg/kg oral/ip dose range of OC potently inhibited 65% – 90% tumour growth both BT-474 and MDA-MB-231 BC cells xenograft models. This was further confirmed by significant reductions of Ki-67, CD31in treated animal tumours by IHC. Conclusion Collectively, these promising results suggest that OC is a unique dual Met/HER2 inhibitory lead entity with excellent therapeutic potential to control breast malignancies with aberrant Met or HER2 activity.